Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

48.28 +0.30 (+0.63%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi-Aventis S.A. ADR

< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Analyst Upgrades Sanofi On COVID-19 Vaccine Optimism
Sanofi SA (NASDAQ:SNY) shares traded higher by 0.4% on Mond... 
Via Benzinga
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2021
Upgrades According to Roth Capital, the prior rating for Seelos Therapeutics Inc (NASDAQ: 
Via Benzinga
Acceleron In Advanced $11B Buyout Talks: Bloomberg
Frothy rumors about possible M&A discussions at Acceleron Pharma Inc (NASDAQ: XLRN) were capped with a Bloomberg report asserting that the Company is... 
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Exposures Product Safety
Pfizer Nabs Booster OK In U.S. — But How Long Will It Hold The Covid Lead?
The FDA allowed the Pfizer-BioNTech Covid booster for some. But rivals are coming. 
Via Investor's Business Daily
Exposures Product Safety
Sanofi, Regeneron, Share Competitive Libtayo Survival Data in 1L NSCLC
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) hope to expand Libtayo into a broader population with a chemo combo regimen. ... 
Via Benzinga
AbbVie's Pain Is Sanofi's and Regeneron's Gain
There are both winners and losers with the new Food and Drug Administration restrictions on JAK inhibitors. 
Via The Motley Fool
Exposures Product Safety
The Week Ahead In Biotech (Sept. 12-18): Calliditas FDA Decision, Adcom Review For Pfizer/BioNTech COVID-19 Vaccine, Oncology Conference And IPOs
Biotech stocks retreated in the holiday-shortened week ending Sept. 10, reversing course from the previous week. Humanigen, Inc. (NASDAQ: HGEN) was among the biggest... 
Via Benzinga
Exposures COVID-19 Product Safety
Week In Review: Sanofi Acquires Kadmon, A US-China Pharma, For $1.9 Billion
France's Sanofi will acquire Kadmon Holdings​​ of New York City in a $1.9 billion deal. In 2019, Kadmon formed a JV with BioNova Pharma to develop its novel lead drug, Rezurock (belumosudil) in China. 
Via Talk Markets
Can Pfizer Beat Sanofi and Regeneron in the Eczema Market?
Pfizer's abrocitinib faces some challenges despite encouraging late-stage results for the drug in treating eczema. 
Via The Motley Fool
EMA Gives Nod To Additional Sites For Pfizer - BioNTech COVID-19 Vaccine
European Medical Agency (EMA) has approved additional manufacturing sites to produce Comirnaty, the COVID-19 vaccine developed by Pfizer Inc (NYSE: PFE) and... 
Via Benzinga
Exposures COVID-19
Sanofi's BTK Inhibitor Disappoints In Phase 3 Autoimmune Disease Trial
Sanofi SA's (NASDAQ: SNY) BTK inhibitor, rilzabrutinib, has flunked its first major clinical test. Rilzabrutinib was Principia Biopharma Inc's one of the... 
Via Benzinga
KDMN Stock: 6 Things to Know About Biopharma Kadmon Holdings as Shares Skyrocket
Kadmon Holdings (KDMN) stock is rising higher on Wednesday following news of a deal with Sanofi (SNY) that comes to $1.9 billion. 
Via InvestorPlace
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE:... 
Via Benzinga
Exposures COVID-19
Kadmon Stock Hits 5-Year High On Sanofi's $1.9 Billion Takeover
Sanofi said Wednesday it will spend $1.9 billion to acquire small biotech Kadmon Holdings, and KDMN stock rocketed to a five-year high. 
Via Investor's Business Daily
Why Kadmon Holdings Stock Is Rocketing Higher Today
Sanofi adds another bolt-on acquisition in what is turning out to be a busy year for the French pharma titan. 
Via The Motley Fool
Sanofi's $1.9 Billion Bet On Kadmon: What You Need to Know
Underlining the focus on inorganic growth, French pharma giant Sanofi (NASDAQ: SNY) announced a big-ticket acquisition just a month after another billion-dollar... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates
August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New... 
Via Benzinga
Glaxo, SK Bioscience Start COVID-19 Vaccine Trial Against AstraZeneca Shot
GlaxoSmithKline Plc (NYSE: GSK) has started Phase 3 clinical study for a COVID-19 vaccine candidate designed by South Korean drugmaker SK Bioscience Co. The... 
Via Benzinga
Exposures COVID-19
Pfizer's Abrocitinib Beats Dupixent Late-stage Eczema Trial
Pfizer Inc (NYSE: PFE) announced topline data from the JADE DARE Phase 3 trial comparing abrocitinib with Sanofi SA (NASDAQ: SNY) - Regeneron... 
Via Benzinga
Dupixent Becomes First Biologic To Show Benefit In Infant Patients With Atopic Dermatitis
A Phase 3 trial evaluating Dupixent (dupilumab) for treating children aged 6 months to 5 years with moderate-to-severe atopic dermatitis met its primary and secondary... 
Via Benzinga
Surprise! Here's the Cheapest COVID Vaccine Stock on the Market Right Now
The least expensive COVID-19 vaccine stock right now isn't one of the leaders in the market -- at least not yet. 
Via The Motley Fool
Exposures COVID-19
Roche's Arthritis Drug, Used As COVID-19 Treatment, Faces Supply Shortage
Roche Holdings AG's (OTCQX: RHHBF) drug Actemra, or tocilizumab, was granted FDA emergency use authorization for critically ill COVID-19 patients after... 
Via Benzinga
Exposures COVID-19 Product Safety
Inside Sanofi's $3.2B Translate Bio Buyout
Before the $3.2 billion acquisition of mRNA player Translate Bio Inc (NASDAQ: TBIO) earlier this month, Sanofi SA (NASDAQ: SNY) expressed interest... 
Via Benzinga
Unusual Options Activity Insight: Sanofi
Sanofi (NASDAQ:SNY) shares experienced unusual options activity on Monday. The stock price moved up to $51.84 following the option alert. Sentiment: BULLISH Option Type: SWEEP... 
Via Benzinga
What Rinvoq's Positive News Means for AbbVie
If the drug can overcome JAK inhibitor-class concerns, it could capture share in the growing atopic dermatitis market. 
Via The Motley Fool
Drug Makers Overseas Are Gaining A Competitive Advantage In The Antibiotics R&D Market; Acurx Pharmaceuticals Ibezapolstat Program Is Helping Level The Field (NASDAQ: ACXP)
Via AB Newswire
FDA Approves Sanofi's Enzyme Therapy For Late-Onset Pompe Disease
The 
Via Benzinga
Exposures Product Safety
Exicure Shares Interim Cavrotolimod Data From Early-Stage Trial In Solid Tumor Patients
Exicure Inc (NASDAQ: XCUR) has reported interim results from Phase 1b/2 trial evaluating cavrotolimod (AST-008) in patients with advanced or metastatic solid... 
Via Benzinga
Stock Market Rally Hits Highs Amid Strong Earnings, Jobs; Square, GM, Etsy Among Key Movers
The Dow, S&P 500 and Nasdaq amid heavy earnings and a hot jobs report. Square, GM and Etsy were notable movers. 
Via Investor's Business Daily
Topics Stocks
Exposures Fossil Fuels US Equities
< Previous 1 2
...
25 26 27 28 29 30 31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.